Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.

[1]  E. Goetghebeur,et al.  Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. , 2019, European urology.

[2]  E. Espinosa,et al.  Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Wilmott,et al.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. , 2018, The Lancet. Oncology.

[4]  K. Kabashima,et al.  Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations , 2018, Front. Oncol..

[5]  Manish R. Sharma,et al.  Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[7]  S. Demaria,et al.  Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers , 2017, Clinical Cancer Research.

[8]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[9]  Bart Neyns,et al.  Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. , 2017, The Lancet. Oncology.

[10]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[11]  L. Brochez,et al.  A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response , 2017, Journal of Translational Medicine.

[12]  S. Berger,et al.  Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade , 2016, Science.

[13]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[14]  B. Neyns,et al.  Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors , 2016, Journal of Translational Medicine.

[15]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[16]  S. Demaria,et al.  Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. , 2015, The Lancet. Oncology.

[17]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[18]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[19]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[20]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[21]  John Wong,et al.  Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. , 2013, International journal of radiation oncology, biology, physics.

[22]  M. Schell,et al.  Stereotactic body radiation therapy: the report of AAPM Task Group 101. , 2010, Medical physics.

[23]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[24]  G. Coukos,et al.  Radiotherapy combination opportunities leveraging immunity for the next oncology practice , 2017, CA: a cancer journal for clinicians.